Biomea Fusion Inc BMEA 深 滬
已收盤 02-06 16:00:00 美东时间
1.22
+0.080
+7.02%
華盛通- 最 高1.22
- 今 開1.17
- 成交量 118.78万股
- 最 低 1.11
- 昨 收 1.14
- 總市值 8625.84万
- 52周最高 3.96
- 市盈率 靜 --
- 換手率 1.68%
- 52周最低 0.8719
- 委 比 -93.85%
- 總股本 7070.36万
- 歷史最高 43.69
- 量 比 0.82
- 振 幅 9.65%
- 歷史最低 0.8719
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JPMorgan’s top short ideas for Q1: FTNT, TXT, IMO and more
J.P. Morgan’s U.S. equity thematic research team surveyed its top-ranked analysts to identify their most compelling structural and tactical short ideas heading into the first quarter of 2026. They fea...
01-24 00:24
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
Biomea Fusion Expects To Enroll First Participant In COVALENT-211 Phase IIb Trial In Q1 2026, Provides Business Updates For This Year
Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today outlined its execution priorities for 2026. The Company enters the year with strong
01-12 21:05
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Biomea Fusion, a clinical-stage biopharmaceutical company, announced that its Interim CEO, Mick Hitchcock, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company will also host one-on-one meetings during the event. A live audio webcast of the presentation and its replay will be available through Biomea’s website. Biomea focuses on developing therapies for diabetes and obesity, targeting metabolic disord...
2025-12-17 12:00
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
Dr. Ralph DeFronzo, a leading expert, highlighted the potential of icovamenib, a menin inhibitor, in treating diabetes during the WCIRDC 2025 conference. He discussed its mechanism of action, clinical results from the COVALENT-111 study, and its combination with GLP-1 therapies. Icovamenib aims to restore beta cell function, addressing a critical need in insulin-deficient diabetes. Biomea Fusion emphasizes its commitment to developing this innova...
2025-12-09 23:35
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Biomea Fusion, a clinical-stage diabetes and obesity company, announced its selection to present long-term follow-up data on icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC) in Los Angeles. The presentation, focusing on the Week 52 data, highlights icovamenib's potential as a paradigm shift in treating type 2 diabetes, particularly for insulin-deficient patients. Icovamenib, an oral menin ...
2025-12-01 21:10
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, a clinical-stage company developing diabetes and obesity treatments, granted a new employee 7,500 non-qualified stock options under its 2023 Inducement Equity Plan, approved on November 17, 2023. The options, which vest quarterly over four years, align with Nasdaq Listing Rule 5635(c)(4) to induce employment.
2025-12-01 21:05
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion, a clinical-stage biopharmaceutical company focused on diabetes and obesity, will participate in two investor conferences: the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York, and the Evercore 8th Annual Healthcare Conference on December 3, 2025, in Coral Gables, FL. The company will host fireside chats and one-on-one meetings at both events. Audio webcasts will be available on Biomea’s website, with...
2025-11-24 12:00
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
